Randomized clinical trial: Combination antiretroviral therapy with tenofovir-emtricitabine and lopinavir-ritonavir in patients with primary biliary cholangitis
- 25 February 2019
- journal article
- research article
- Published by University of Toronto Press Inc. (UTPress) in Canadian Liver Journal
- Vol. 2 (1) , 31-44
Abstract
Background: Prior studies using reverse transcriptase inhibitors to treat a human betaretrovirus (HBRV) in patients with primary biliary cholangitis (PBC) resulted in a 21% reduction in alkaline phosphatase (ALP). Herein, we studied the safety and efficacy of combination tenofovir-emtricitabine (TDF/FTC) and lopinavir-ritonavir (LPRr) in PBC patients unresponsive to ursodeoxycholic acid (UDCA). Methods: A double-blind randomized controlled trial was performed in patients on UDCA for 6 months or more with ALP levels greater than two-fold the upper limit of normal or bilirubin greater than the upper limit of normal. Patients were randomized to daily TDF/FTC 300/200 mg and LPRr 800/200 mg versus identical placebo for 6 months. The primary endpoint was reduction of ALP below 1.67 × ULN or normalization of bilirubin. HBRV DNA levels were assessed in peripheral blood mononuclear cells (PBMC) using digital droplet polymerase chain reaction. Results: The enrolment was limited to 13 patients because most patients were unable to tolerate LPRr due to the development of gastrointestinal symptoms. No difference in the primary endpoint was achieved. A significant reduction was observed in ALP by 25% (P < 0.05) and in HBRV proviral load (P < 0.05) after 6 months of combination antiretroviral therapy. The majority of patients had diminished levels of LPRr after 6 months’ therapy suggesting inadequate intake of protease inhibitor toward the end of the study. Conclusions: Combination anti-retroviral therapy resulted in improvement in hepatic biochemistry with reduction in proviral load. The frequency of side effects from LPRr in patients with PBC exceeds the frequency reported for HIV, warranting the search for better tolerated combinations in future studies.Keywords
This publication has 39 references indexed in Scilit:
- The Genetics of Complex Cholestatic DisordersGastroenterology, 2013
- Highly Precise Measurement of HIV DNA by Droplet Digital PCRPLOS ONE, 2013
- American Association for the Study of Liver Diseases Endpoints Conference: Design and Endpoints for Clinical Trials in Primary Biliary CirrhosisHepatology, 2010
- Cyclosporine A inhibits in vitro replication of betaretrovirus associated with primary biliary cirrhosisLiver International, 2009
- Clinical trial: randomized controlled study of zidovudine and lamivudine for patients with primary biliary cirrhosis stabilized on ursodiolAlimentary Pharmacology & Therapeutics, 2008
- Human RNA “Rumor” Viruses: the Search for Novel Human Retroviruses in Chronic DiseaseMicrobiology and Molecular Biology Reviews, 2008
- Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosisGut, 2005
- Virological and Pharmacological Parameters Predicting the Response to Lopinavir-Ritonavir in Heavily Protease Inhibitor-Experienced PatientsAntimicrobial Agents and Chemotherapy, 2005
- Cloning the human betaretrovirus proviral genome from patients with primary biliary cirrhosis†Hepatology, 2004
- Reverse transcriptase-dependent and -independent phases of infection with mouse mammary tumor virus: implications for superantigen function.Journal of Experimental Medicine, 1994